According to the narrow specific criteria indicated by Cook, AVI would not work.
Cook mentioned they would be interested in a company with a drug that is near term (e.g. through, or almost through phase III) and with a bit of a black hole in terms of any trailing opportunities (e.g. maybe no further pipeline drugs beyond Phase I or early Phase II).
avi biopharma , page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)